# A Study of Mevrometostat With Enzalutamide in People With Prostate Cancer Who Have Previously Received Androgen Receptor Pathway Inhibitor Therapy

> **NCT07592910** · PHASE2 · NOT_YET_RECRUITING · sponsor: **Prostate Cancer Clinical Trials Consortium** · enrollment: 60 (estimated)

## Conditions studied

- Metastatic Castrate Resistant Prostate Cancer (mCRPC)
- Prostate Cancer (Adenocarcinoma)

## Interventions

- **DRUG:** Mevrometostat
- **DRUG:** Enzalutamide

## Key facts

- **NCT ID:** NCT07592910
- **Lead sponsor:** Prostate Cancer Clinical Trials Consortium
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-08
- **Primary completion:** 2029-05
- **Final completion:** 2029-08
- **Target enrollment:** 60 (ESTIMATED)
- **Last updated:** 2026-05-18

## Collaborators

- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07592910

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07592910, "A Study of Mevrometostat With Enzalutamide in People With Prostate Cancer Who Have Previously Received Androgen Receptor Pathway Inhibitor Therapy". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT07592910. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*